HAE 8-K
Haemonetics Corp (HAE)
8-K
2025-07-25
For: 2025-07-24
View Original
Added on
April 07, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 24, 2025
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: 781 -848-7100
(Former name or former address, if changed since last report.)
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | |||||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | ||
Emerging Growth Company | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | ||
Item 5.07 Submission of Matters to a Vote of Security Holders.
The 2025 Annual Meeting of Shareholders of Haemonetics Corporation (the “Company”) was held on Thursday, July 24, 2025. Of the 48,041,228 shares outstanding and entitled to vote at the meeting, 45,613,041 shares were represented at the meeting, constituting a quorum of 94.95%.
The results of the votes for each proposal considered at the meeting are set forth below:
1. The shareholders elected each of Christopher A. Simon, Robert E. Abernathy, Diane M. Bryant, Michael J. Coyle, Charles J. Dockendorff, Lloyd E. Johnson, Mark W. Kroll, Claire Pomeroy and Ellen M. Zane as directors for one-year terms expiring in 2026 based upon the following votes:
| Nominees | For | Withhold | Broker Non-Votes | |||||||||||||||||
| Christopher A. Simon | 43,756,151 | 99,166 | 1,757,724 | |||||||||||||||||
| Robert E. Abernathy | 43,061,317 | 794,000 | 1,757,724 | |||||||||||||||||
| Diane M. Bryant | 43,568,258 | 287,059 | 1,757,724 | |||||||||||||||||
| Michael J. Coyle | 43,670,835 | 184,482 | 1,757,724 | |||||||||||||||||
| Charles J. Dockendorff | 42,588,774 | 1,266,543 | 1,757,724 | |||||||||||||||||
| Lloyd E. Johnson | 43,151,041 | 704,276 | 1,757,724 | |||||||||||||||||
| Mark W. Kroll | 42,739,455 | 1,115,862 | 1,757,724 | |||||||||||||||||
| Claire Pomeroy | 43,567,795 | 287,522 | 1,757,724 | |||||||||||||||||
| Ellen M. Zane | 43,066,065 | 789,252 | 1,757,724 | |||||||||||||||||
2. The shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers based upon the following votes:
| For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 43,016,961 | 585,626 | 252,730 | 1,757,724 | |||||||||||||||||
3. The shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending March 28, 2026 based upon the following votes:
| For | Against | Abstain | ||||||||||||||||||
| 43,843,396 | 1,525,114 | 244,531 | ||||||||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HAEMONETICS CORPORATION | ||||||||||||||
| July 25, 2025 | By: | /s/ Christopher A. Simon | ||||||||||||
| Name: | Christopher A. Simon | |||||||||||||
| Title: | President and Chief Executive Officer | |||||||||||||